Session: FP29-Adrenal Tumors & Pheochromocytoma
Room 134 (Moscone Center)
Poster Board MON-2
DESIGN & METHODS: CTC analysis was performed in 14 ACC and 10 adrenocortical adenoma (ACA) patients. Blood samples obtained before (n=3 patients) and after (n=10 patients) surgery were filtered on Screencell devices (Screencell®), polycarbonate membranes with 8 µm pores, which isolate CTC on size-basis.
RESULTS: CTC were isolated in all ACC but not in ACA samples. Immunocytochemistry on CTC, compared to the primary tumors, revealed positivity for adrenocortical markers, confirming the adrenocortical origin. When ACC patients were stratified in two classes according to the cut-off of the median value of the clinical parameters (tumor diameter, Ki67, Weiss) or to the presence/absence of metastasis, a statistically significant difference was found in the number of post-surgical CTC only when diameter (CTC/ml mean±SD: 2.70±3.70 vs 0.59±0.67, P=0.028 for diameter>/=8 and<8cm, respectively) and metastatic stage (CTC/ml mean±SD: 3.91±4.83 vs 0.70±0.70, P=0.031, for stage=4 versus the others, respectively) were considered
CONCLUSIONS: Our findings provide the first evidence that circulating tumor cells (CTC) may represent a valid and useful marker to support diagnosis in adrenocortical tumor pathologies. Moreover, CTC seem to correlate with some clinical parameters. Although very preliminary, these results, which need confirmation in larger series, suggest a potential use of this so-called “liquid biopsy” for prognosis and non-invasive monitoring progression and response to treatments.
Nothing to Disclose: ML, PP, CS, FS, EC, LC, GP, VP, GN, MM
*Please take note of The Endocrine Society's News Embargo Policy at http://www.endo-society.org/endo2013/media.cfm
See more of: Abstracts - Orals, Featured Poster Presentations, and Posters